Treating Helicobacter pylori infection in the face of growing antibiotic resistance.
Treating Helicobacter pylori infection in the face of growing antibiotic resistance.
Rev Esp Enferm Dig. 2019 Sep 03;111:653-654
Authors: Fernández Salazar L, Valle Muñoz J
Abstract
Helicobacter pylori eradication cures most peptic ulcers and non-atrophic chronic gastritis, and may potentially prevent over 70% of gastric cancers. In the late 1980s, shortly after the discovery of H. pylori, eradication therapy was established based on the use of two antibiotics (amoxicillin and clarithromycin) and one proton-pump inhibitor for 7 or 10 days (OCA7, OCA10). This therapy, recommended during the first Maastricht Consensus Conference, obtained eradication rates above 90%, and was equally effective everywhere around the world. However, over time, H. pylori has developed resistance to several antibiotics.
PMID: 31476871 [PubMed - as supplied by publisher]
Source: Revista Espanola de Enfermedades Digestivas - Category: Gastroenterology Tags: Rev Esp Enferm Dig Source Type: research
More News: Amoxicillin | Biaxin | Cancer | Cancer & Oncology | Clarithromycin | Conferences | Gastric (Stomach) Cancer | Gastritis | Gastroenterology | Helicobacter Pylori | Peptic Ulcer | Proton Pump Inhibitors PPIs